In a phase 2b clinical trial, Beckley Psytech has started treating the first subject for BPL-003, an intranasal synthetic formulation of the psychedelic chemical 5-MeO-DMT intended for patients with treatment-resistant depression. With FDA clearance for investigational new medication status in February, this groundbreaking research represents the biggest controlled examination into the potential of 5-MeO-DMT, involving 40 locations throughout Australia, Europe, and the US.
The NBA champion and New York Knick will premier his new flower brand at Torches…
By: LMC Legacy to licensed is the motto for authentic New York brands entering the…
Vlad Bautista began his cannabis empire in Harlem's Sugar Hill. Nearly 30 years later, his…
Cannabis terpenes are the compounds responsible for the aromatic profile of each strain; they are…
Authoritarians cannot let go of the value that keeping the most widely used illicit substance…
No need to wait until May—April showers bring dank flowers for every strain. A big…